Literature DB >> 28899697

Implementation of a human podocyte injury model of chronic kidney disease for profiling of renoprotective compounds.

Vivek C Abraham1, Loan N Miller2, Steve D Pratt3, Brent Putman2, Laura Kim3, Sujatha M Gopalakrishnan3, Andrew King2.   

Abstract

Degradation of podocyte structural integrity and function are hallmarks of proteinuric chronic kidney disease. In vivo, injury of podocytes manifests itself in the form of disruption of foot process morphology and associated cytoskeletal architecture, de-differentiation, and loss of adhesion to the glomerular basement membrane. Given the critical role played by this highly specialized cell type in maintaining glomerular filtration, there is a need for improved physiologically relevant cellular models that enable detection of disease-relevant indicators of podocyte perturbation. We have addressed this need by evaluating a subclone of conditionally immortalized human podocytes through quantitative benchmarking against freshly isolated primary human podocytes. Benchmarking was performed by measuring key phenotypic parameters, expression of podocyte specific proteins and multiparametric responses to stressors that model different aspects of podocyte perturbation. We subsequently employed the subcloned cells to profile the protective activity of structurally distinct adenosine kinase inhibitors. Our results support the translatability of our cellular model and set the stage for broader screening of renoprotective compounds with a view to eventually treat proteinuric kidney disease.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adenosine kinase; Chronic kidney disease; Cytoskeleton; Diabetic nephropathy; Podocyte

Mesh:

Year:  2017        PMID: 28899697     DOI: 10.1016/j.ejphar.2017.09.006

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  3 in total

1.  How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development.

Authors:  Monika Schäfer-Korting; Christian Zoschke
Journal:  Handb Exp Pharmacol       Date:  2021

2.  Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.

Authors:  Efrat Harel; Jun Shoji; Vivek Abraham; Loan Miller; Zoltan G Laszik; Andrew King; Dejan Dobi; Gyula Szabo; Byron Hann; Minnie M Sarwal; Charles S Craik; Flavio Vincenti
Journal:  Transplantation       Date:  2020-01       Impact factor: 5.385

Review 3.  Biochemical composition of the glomerular extracellular matrix in patients with diabetic kidney disease.

Authors:  María M Adeva-Andany; Natalia Carneiro-Freire
Journal:  World J Diabetes       Date:  2022-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.